Fisher Asset Management LLC Has $7.87 Million Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Fisher Asset Management LLC increased its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 7.8% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 68,270 shares of the company’s stock after acquiring an additional 4,930 shares during the quarter. Fisher Asset Management LLC owned about 0.07% of Neurocrine Biosciences worth $7,866,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the business. Sumitomo Mitsui DS Asset Management Company Ltd increased its holdings in shares of Neurocrine Biosciences by 0.8% during the 2nd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 11,436 shares of the company’s stock worth $1,574,000 after acquiring an additional 90 shares during the last quarter. Fifth Third Bancorp increased its holdings in shares of Neurocrine Biosciences by 14.7% during the 2nd quarter. Fifth Third Bancorp now owns 716 shares of the company’s stock worth $99,000 after acquiring an additional 92 shares during the last quarter. Total Clarity Wealth Management Inc. increased its holdings in shares of Neurocrine Biosciences by 4.3% during the 2nd quarter. Total Clarity Wealth Management Inc. now owns 2,433 shares of the company’s stock worth $335,000 after acquiring an additional 100 shares during the last quarter. Commerce Bank boosted its stake in Neurocrine Biosciences by 2.6% in the 3rd quarter. Commerce Bank now owns 4,199 shares of the company’s stock valued at $484,000 after purchasing an additional 108 shares during the period. Finally, Caprock Group LLC boosted its stake in Neurocrine Biosciences by 7.0% in the 2nd quarter. Caprock Group LLC now owns 1,669 shares of the company’s stock valued at $230,000 after purchasing an additional 109 shares during the period. 92.59% of the stock is owned by institutional investors and hedge funds.

Neurocrine Biosciences Stock Performance

Neurocrine Biosciences stock opened at $126.59 on Friday. Neurocrine Biosciences, Inc. has a 52 week low of $110.81 and a 52 week high of $157.98. The stock has a fifty day moving average of $119.09 and a 200-day moving average of $131.67. The stock has a market capitalization of $12.82 billion, a P/E ratio of 33.94 and a beta of 0.35.

Analyst Ratings Changes

Several research firms recently issued reports on NBIX. Barclays reduced their price target on Neurocrine Biosciences from $180.00 to $160.00 and set an “overweight” rating for the company in a research note on Monday, September 9th. Raymond James restated an “outperform” rating and issued a $155.00 price target on shares of Neurocrine Biosciences in a research note on Thursday, October 10th. Royal Bank of Canada reduced their price target on Neurocrine Biosciences from $136.00 to $133.00 and set a “sector perform” rating for the company in a research note on Friday, October 4th. Guggenheim boosted their price target on Neurocrine Biosciences from $170.00 to $180.00 and gave the company a “buy” rating in a research note on Friday, August 2nd. Finally, Piper Sandler upgraded Neurocrine Biosciences from a “neutral” rating to an “overweight” rating and boosted their price target for the company from $131.00 to $159.00 in a research note on Thursday, August 29th. Five investment analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $163.91.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.